EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Abstract

Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.

Study Design: A prospective, observational cohort study.

Place and Duration of Study: Pak Emirates Military Hospital Rawalpindi, Army Medical College Rawalpindi, from Jan 2018 to Dec 2018.

Methodology: A total of 114 patients infected with genotype 3 were segregated into two groups according to their treatment status with 57 patients in each group. They received treatment according to the World Health Organization guidelines to assess the efficacy in terms of sustained virological response upon 12 weeks of completion of treatment (SVR 12) and to evaluate changes in serum alanine aminotransferase (ALT), total bilirubin, albumin and prothrombin time (PT). The results were comparatively analyzed between the groups.

Results: The percentage of patients attaining SVR 12 was nearly same in both the groups (94.7% vs 93%). Improvement in ALT, total bilirubin, serum albumin and prothrombin time was highly significant (p<0.001). When all the parameters were statistically compared, no substantial difference in the results was obtained.

Conclusion: This study exhibited that the regimen consisting of sofosbuvir and daclatasvir is equally effective and beneficial for newly diagnosed and earlier treatment failure patients by eradicating the virus and improving liver function parameters which ultimately result in improved quality of life.